2012
DOI: 10.1007/s40263-012-0022-1
|View full text |Cite
|
Sign up to set email alerts
|

Intranasal Oxytocin as an Adjunct to Risperidone in Patients with Schizophrenia

Abstract: Oxytocin as an adjunct to risperidone tolerably and efficaciously improves positive symptoms of schizophrenia. In addition, effects on negative and total psychopathology scores were statistically significant, but likely to be clinically insignificant. The interesting findings from the present pilot study need further replication in a larger population of patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
96
1

Year Published

2013
2013
2022
2022

Publication Types

Select...
4
4
1

Relationship

0
9

Authors

Journals

citations
Cited by 94 publications
(99 citation statements)
references
References 35 publications
2
96
1
Order By: Relevance
“…A positive correlation between SZ progression and oxytocin levels in the central nervous system has been observed [Beckmann et al, 1985], and it is plausibly explained by a decreased sensitivity to the hormone [Glovinsky et al, 1994;Sasayama et al, 2012;Strauss et al, 2015]. Treatment with oxytocin indeed improves the performance of verbal memory learning tasks in SZ patients [Feifel et al, 2012], and attenuates the negative symptoms of the disease [Feifel et al, 2010;Modabbernia et al, 2013;Davis et al, 2014;Gibson et al, 2014].…”
Section: Behavioral Traits and Neuroendocrine Impairmentmentioning
confidence: 95%
“…A positive correlation between SZ progression and oxytocin levels in the central nervous system has been observed [Beckmann et al, 1985], and it is plausibly explained by a decreased sensitivity to the hormone [Glovinsky et al, 1994;Sasayama et al, 2012;Strauss et al, 2015]. Treatment with oxytocin indeed improves the performance of verbal memory learning tasks in SZ patients [Feifel et al, 2012], and attenuates the negative symptoms of the disease [Feifel et al, 2010;Modabbernia et al, 2013;Davis et al, 2014;Gibson et al, 2014].…”
Section: Behavioral Traits and Neuroendocrine Impairmentmentioning
confidence: 95%
“…For the cholinergic system, drugs that activate cholinergic receptors, including partial alpha 7-nicotinic agonists, currently show the most promise. Finally, exogenous oxytocin (delivered by intranasal spray) has been found to improve negative symptoms in two studies (Feifel 2012;Modabbernia et al 2013). It should be noted, however, that the relevant studies typically used older trial design and assessment methods, and many of them targeted cognition or social cognition, rather than negative symptoms, as the primary treatment outcome.…”
Section: Recent Developmentsmentioning
confidence: 99%
“…22,23 There has been much investigation of the possible benefits of intranasal oxytocin for schizophrenia, 24 with improvements recorded in domains such as clinical symptom ratings 25 and social cognition. 26 Intranasal oxytocin has also been studied for autism.…”
Section: Intranasal Oxytocinmentioning
confidence: 99%